Skip to main content

Table 1 Comparison of mDSI/mHD index evaluation for initially rejected and finally accepted volumes

From: Quality assurance of radiotherapy in the ongoing EORTC 1420 “Best of” trial for early stage oropharyngeal, supraglottic and hypopharyngeal carcinoma: results of the benchmark case procedure

Index mDSI (SD) mHD (SD)
Volumes(n = 67) First Final Difference First Final Difference
Planning organ-at-risk volume of the brainstem (3) 0.74 (0.16) 0.75 (0.14) 0.01 (0.02) 8.94 (4.26) 7.88 (3.38) − 1.1 (1.1)
Cervical esophagus (4) 0.49 (0.10) 0.33 (0.16) − 0.16 (0.13) 27.22 (11.98) 18.83 (8.44) − 8.4 (14.0)
Cricoid pharyngeal inlet (5) 0.36 (0.22) 0.38 (0.09) 0.03 (0.20) 13.42 (6.75) 13.19 (3.87) − 0.2 (9.6)
Contralateral sub-mandibular gland (1) 0.83 (.) 0.83(.) 0.00(.) 5.37 (.) 5.37 (.) 0.0 (.)
Extended oral cavity—PTV (5) 0.76 (0.02) 0.84 (0.08) 0.08 (0.06) 26.36 (4.22) 15.56 (9.19) − 10.8 (9.7)
Glottis (3) 0.43 (0.19) 0.56 (0.15) 0.14 (0.34) 13.28 (7.63) 8.58 (4.89) − 4.7 (12.3)
Mandible (6) 0.88 (0.04) 0.91 (0.02) 0.03 (0.03) 19.84 (8.59) 6.75 (4.98) − 13.1 (8.8)
Pharyngeal constrictor muscles (8) 0.47 (0.16) 0.59 (0.09) 0.12 (0.12) 30.34 (8.83) 19.70 (3.65) − 10.6 (8.4)
Prophylactic PTV (19) 0.70 (0.13) 0.78 (0.05) 0.07 (0.13) 26.23 (16.33) 15.64 (4.59) − 10.6 (17.1)
Therapeutic PTV (8) 0.64 (0.15) 0.70 (0.10) 0.06 (0.11) 11.14 (4.05) 10.17 (2.31) − 1.0 (3.7)
Planning organ-at-risk volume of the spinal cord (3) 0.78 (0.07) 0.80 (0.09) 0.01 (0.02) 6.61 (2.73) 6.68 (2.80) 0.1 (1.1)
Supraglottic larynx (2) 0.42 (0.31) 0.41 (0.29) − .01 (0.02) 21.03 (18.35) 23.33 (15.09) 2.3 (3.3)